Charles Leath Iii, G. Scambia, R. Villalobos, N. Colombo, D. Cibula, M. Bidziński, Jae-Weon Kim, J. Nam, R. Mądry, C. Hernández, P. Mora, S. Ryu, M. Ah-See, E. Lowe, N. Lukashchuk, Dave Carter, R. Penson
{"title":"最新的摘要报告:brca突变的铂敏感复发卵巢癌患者在SOLO3中接受奥拉帕尼治疗或非铂化疗的总生存率与既往化疗线数有关","authors":"Charles Leath Iii, G. Scambia, R. Villalobos, N. Colombo, D. Cibula, M. Bidziński, Jae-Weon Kim, J. Nam, R. Mądry, C. Hernández, P. Mora, S. Ryu, M. Ah-See, E. Lowe, N. Lukashchuk, Dave Carter, R. Penson","doi":"10.1136/ijgc-2022-igcs.1","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":348678,"journal":{"name":"Oral Abstracts (Regular and Late-Breaking Submission)","volume":"2022 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"LB001/#1731 Late-breaking abstract presentation: overall survival by number of prior lines of chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer receiving olaparib treatment or non-platinum chemotherapy in SOLO3\",\"authors\":\"Charles Leath Iii, G. Scambia, R. Villalobos, N. Colombo, D. Cibula, M. Bidziński, Jae-Weon Kim, J. Nam, R. Mądry, C. Hernández, P. Mora, S. Ryu, M. Ah-See, E. Lowe, N. Lukashchuk, Dave Carter, R. Penson\",\"doi\":\"10.1136/ijgc-2022-igcs.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":348678,\"journal\":{\"name\":\"Oral Abstracts (Regular and Late-Breaking Submission)\",\"volume\":\"2022 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Abstracts (Regular and Late-Breaking Submission)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2022-igcs.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Abstracts (Regular and Late-Breaking Submission)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2022-igcs.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
LB001/#1731 Late-breaking abstract presentation: overall survival by number of prior lines of chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer receiving olaparib treatment or non-platinum chemotherapy in SOLO3